Hong Kong-listed Yingpai Pharmaceutical (07630.HK) continued its upward trend, rising nearly 40%. The company announced that the Committee on Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion

2026-09-21

Hong Kong-listed Yingpai Pharmaceutical (07630.HK) continued its upward trend, rising nearly 40%. The company announced that the Committee on Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion recommending marketing authorization (MA) for the drug Sepalna.